2

USTR’s Request for Comments on ACTA

USTR has issued a request for comments on ACTA. The deadline for submissions is February 15, 2011. The notice gives very little guidance regarding the issues the USTR would like addressed in the comments.


[Billing Code 3190-W1-P]

Office of the United States Trade Representative

Anti-Counterfeiting Trade Agreement: Request for Comments from the Public

Agency: Office of the United States Trade Representative

Action: Request for written submissions from the public

Continue Reading

Uncategorized

Notes from meeting with USTR on the TPP IPR chapter

Today USTR provided some additional insight into negotiations of a regional, Asia-Pacific trade agreement, known as the Trans-Pacific Partnership (TPP) Agreement. The USTR web page on the TPP negotiations is http://www.ustr.gov/tpp. At present, the TPP negotiators include Australia, Brunei Darussalam, Chile, New Zealand, Peru, Singapore and Vietnam. Japan and Canada have expressed interest in joining the negotiations, and USTR clearly would like to design an agreement that will be open to other countries. Our discussions focused on the intellectual property chapter in the agreement. Continue Reading

Uncategorized

NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)

13 December 2010

Drugs@FDA
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998

What is Herceptin? How does it work?

Continue Reading

Uncategorized

Statements by KEI and others on NIH rejection of Fabrazyme March-In Request

For background on the Fabrazyme case, see: https://www.keionline.org/fabrazyme

The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.

Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)

Continue Reading

Notes from EU Parliament meeting on innovation+access for medical technologies

Today I am attending a meeting at the European Parliament on new models of innovation for medical technologies. The event was organized by three MEPs, Thijs Berman, Eva Joly and Carl Schlyter, in collaboration with the European Parliament Working Group on Innovation, Access to Medicines and Poverity-Related Diseaes, and several consumer rights, public health and development NGOs (TACD, Health Action International, KEI, Oxfam and IQsensato).

Continue Reading

Uncategorized

A KEI note to Library of Congress about ACTA text

From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500

This note cites several areas where US law is plainly inconsistent with
ACTA.

In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
https://www.keionline.org/node/980

Some examples of inconsistencies between ACTA and US law

Continue Reading

Uncategorized

KEI statement at SCCR 21

This was our 400 word statement at the WIPO SCCR 21.

Statement of KEI at WIPO SCCR 21, November 11, 2010

There should be a compelling rationale for creating new global norms for copyrights.

KEI opposes work on a new broadcasting treaty, and supports work on performers treaty.

KEI supports work at the SCCR on new possible norms for copyright limitations and exceptions, particularly as regards to access to knowledge, and uses of new technologies.

Continue Reading